604 related articles for article (PubMed ID: 9425393)
1. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
2. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
[TBL] [Abstract][Full Text] [Related]
3. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
Rigamonti AE; Bonomo SM; Cella SG; Müller EE
J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
[TBL] [Abstract][Full Text] [Related]
4. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
Rigamonti AE; Cavallera G; Bonomo S; Deghenghi R; Locatelli V; Cella SG; Müller EE
Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
[TBL] [Abstract][Full Text] [Related]
7. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.
Achermann JC; Hindmarsh PC; Robinson IC; Matthews DR; Brook CG
Clin Endocrinol (Oxf); 1999 Nov; 51(5):575-85. PubMed ID: 10594518
[TBL] [Abstract][Full Text] [Related]
8. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
9. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.
Massoud AF; Hindmarsh PC; Brook CG
J Clin Endocrinol Metab; 1996 Dec; 81(12):4338-41. PubMed ID: 8954038
[TBL] [Abstract][Full Text] [Related]
10. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
[TBL] [Abstract][Full Text] [Related]
11. Direct effects of corticotrophin-releasing hormone on stimulated growth hormone secretion.
Raza J; Massoud AF; Hindmarsh PC; Robinson IC; Brook CG
Clin Endocrinol (Oxf); 1998 Feb; 48(2):217-22. PubMed ID: 9579235
[TBL] [Abstract][Full Text] [Related]
12. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
[TBL] [Abstract][Full Text] [Related]
13. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
15. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
[TBL] [Abstract][Full Text] [Related]
16. Hexarelin induced growth hormone release is influenced by exogenous growth hormone.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1995 Nov; 43(5):617-21. PubMed ID: 8548947
[TBL] [Abstract][Full Text] [Related]
17. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans.
Di Vito L; Broglio F; Benso A; Gottero C; Prodam F; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Ghigo E; Arvat E
Clin Endocrinol (Oxf); 2002 May; 56(5):643-8. PubMed ID: 12030916
[TBL] [Abstract][Full Text] [Related]
18. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.
Conley LK; Gaillard RC; Giustina A; Brogan RS; Wehrenberg WB
J Endocrinol; 1998 Sep; 158(3):367-75. PubMed ID: 9846166
[TBL] [Abstract][Full Text] [Related]
19. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
20. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
